Navigation Links
Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
Date:5/11/2011

NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines

http://www.reportlinker.com/p0491872/Biotech-MA-and-Licensing-Strategies---Co-development-Agreements-are-Poised-to-Increase-in-the-Future-to-Counter-Drying-Pipelines.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines

Summary

GBI Research's pharmaceutical research, "Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines", provides insights into the global biotech M&A and licensing strategies. The report provides an in-depth analysis of the major M&A trends in the biotech industry along with the major drivers leading to an increased M&A activity in the current biotech industry. The report also delves into the M&A scenario in RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market. In addition, the report also analyzes the top 10 biotech companies with respect to the licensing agreement activities.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis revealed that acquisitions, as an M&A strategy, dominate the biotech industry with a total of 72% of the M&A deals involving acquisitions. Acquisition strategy was adopted by biotech companies to have high speed access to resources, avoid barriers of entry and expand their portfolio of products and to improve their asset valuation. On the other hand, co-development deals dominates the licensing strategies landscape as compared to licensing agreements and are expected to increase at a higher rate in future. Co-development deals in the biotech industry witnessed a drastic increase in 2010 from 2009. There were 241 co-development activities that occurred in the year 2009 compared to 216 that occurred between January 2010 and August 2010. RNA therapeutics pipeline is the most promising with more than 89% of the licensing deals occurred for discovery and preclinical stage of development. The trend indicates that the future of RNA therapeutic research and development will be prosperous for at least the next five years.

Scope

The Scope of this report includes -

- Major market trends that are expected to shape the licensing and deal making in biotech industry

- Key drivers that have a significant impact on licensing and deal making in biotech.

- Licensing and deal making market trends across five segments which include RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market.

- Licensing and deal making market segmentation by phase, type, geography and value

- Competitive benchmarking of leading biotech companies active in licensing and deal making

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the biotech industry.

- Enable better product lifecycle management by identifying key phases of product licensing agreements.

- Develop segment specific strategies for licensing and deal making in biotech

- Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 7

2 Biotech M&A and Licensing Strategies – Introduction 9

2.1 GBI Research Report Guidance 10

3 M&A Trends in the Biotech Industry 11

3.1 Top 10 Biotech Mergers & Acquisitions 11

3.1.1 Segmentation of M&A Deals by Deal Value: Small Biotech Firms were the Easy Targets for Acquisitions 11

3.2 Shift in Trend from 'Big pharma' to 'Big Bio-Pharmaceutical Companies 11

3.3 Trends towards Diversification Leads to the Integration of Pharmaceuticals and Medical Device's Segment of the Healthcare Industry 11

3.3.1 Conclusion 11

3.4 Biotech M&A Market Drivers 12

3.4.1 Huge Investments in Biotech R&D Resulting in Strong Product Pipeline 12

3.4.2 Higher Approval Rates for Biotech Products have Contributed to the Growth of the Biotechnology Industry 12

3.4.3 High Unmet Needs in Life Threatening Diseases are Driving the Biotechnology Market and M&A Activities 12

3.4.4 Patent Expiries of Pharmaceutical Blockbusters: Pharmaceutical Companies are Focusing on Biologics Due to Their Lack of Patent Expiry in Recent Years 13

3.4.5 Strong Growth in the Market for Cancer and Autoimmune Diseases 14

3.4.6 Lack of Patent Expiry Ensures a Continuous Stream of Revenue 14

3.4.7 Increasing Interest of Big Pharma Companies in the Biotech Industry 14

3.5 Key Takeaway 14

4 M&A Scenario in the Global Landscape 15

4.1 M&A Activities in the Biotech Industry 15

4.2 Licensing Agreements in the Biotech Industry 26

4.3 Co-development Activities in the Biotech Industry 30

5 M&A Scenario in RNA Therapeutics 35

5.1 Big Pharmaceutical Companies Relentlessly Attempting to Unlock RNA Therapy Potential 36

5.2 Influx of Huge Venture Capitalist Funding into Small and Medium Biotech Companies Venturing into RNA Therapeutics Development 36

5.2.1 Dicerna Pharmaceuticals 36

5.2.2 Cequent Pharmaceuticals 36

5.2.3 Prosensa 36

5.2.4 Cylene Pharmaceuticals 37

5.3 High Value Collaborations involving RNA Therapies 37

5.3.1 ISIS Pharmaceuticals 37

5.3.2 Alnylam 37

5.3.3 Silence Therapeutics and AstraZeneca 37

5.3.4 Santaris Pharma and Wyeth Pharmaceuticals 37

5.4 Large Pharmaceutical and Biotechnology Companies are Vying for Major Acquisitions in the RNA Therapeutics Market 38

5.4.1 Thermo Fisher Scientific and Open Biosystems 38

5.4.2 Roche and Mirus Bio 38

5.5 R&D Licensing Agreements 39

5.5.1 Deals by Phase 39

5.5.2 Deals by Geography 40

5.5.3 Deals by Licensing Type 41

5.5.4 Deals by Value ($) 42

5.5.5 Discovery/Development 43

5.5.6 Preclinical 48

5.5.7 Phase I 49

5.5.8 Phase II 49

5.5.9 Phase III 50

6 M&A Scenario in Monoclonal Antibodies 51

6.1 Overview 51

6.1.1 Emergent BioSolutions Acquires Avanir Pharmaceuticals 52

6.1.2 MacroGenics Acquires Raven Biotechnologies 52

6.1.3 Thermo Fisher acquires Affinity BioReagents 52

6.2 R&D Licensing Agreements 53

6.2.1 Deals by Phase 53

6.2.2 Deals by Geography 54

6.2.3 Deals by Licensing Type 54

6.2.4 Deals by Value ($) 55

6.2.5 Preclinical 56

6.2.6 Phase I 57

6.2.7 Phase II 58

6.2.8 Phase III 59

6.2.9 Approved 59

7 M&A Scenario in Biomarkers 60

7.1 Mergers and Acquisitions 60

7.1.1 Thermo Fisher Scientific Inc Merges with B.R.A.H.M.S. AG 60

7.1.2 Clinical Data Inc to Acquire Avlon Pharmaceuticals 60

7.1.3 OSI Pharmaceuticals and AVEO Enter Collaborative Alliance 60

7.1.4 PEP Products Inc. and Interleukin Genetics Inc. Enter Collaborative Alliance 61

7.1.5 Pfizer Canada signs Alliance Deal with the Centre of Excellence for the Prevention of Organ Failure (Proof) 61

7.1.6 Millipore Corporation Acquires Guava Technologies 61

7.1.7 SuperGen Inc. Acquires Montigen Pharmaceuticals, Inc. 61

7.1.8 National Institute of Allergy and Infectious Diseases (NIAID) Enters Collaborative Alliance with Caprion Proteomics Inc. 61

7.1.9 Entelos Inc Acquires Iconix Biosciences 61

7.1.10 Vermillion Inc Acquires Ciphergen Biosystems 61

7.1.11 Collaborative Alliance with CBMS-MITS JPMO 62

7.2 Mergers and Acquisition Analysis by Deal Type 62

7.3 Mergers and Acquisition by Year of Consolidations 63

7.4 Mergers and Acquisitions by Geography 64

7.5 Mergers and Acquisitions by Deal value 65

7.6 Partnership Deals 66

7.6.1 Partnership Deals by Year 66

7.6.2 Partnership Deals by Indication 67

7.6.3 Partnership Deals by Deal Type 68

7.6.4 Partnership Deals by Geography 69

7.6.5 Partnership Deals by Companies 70

7.7 M&A Landscape 71

7.7.1 M&A Deals by Value 71

7.7.2 M&A Deals by Geography 72

7.7.3 M&A Deals by Companies 73

7.7.4 Top Five M&A Deals by Value 74

7.8 Key Takeaway 76

8 M&A Scenario in Biosimilars 77

8.1 Mergers & Acquisitions 77

8.1.1 Merck Acquires Insmed's Follow-On Biologics for $130m 77

8.1.2 Teva and Lonza Joint Venture Targets Biosimilars 77

8.1.3 GTC Enters a Follow-On-Biologic Founder Development Collaboration with AgResearch 77

8.2 Licensing Deals 78

8.2.1 Innogene Seals Deal with CIMAB to Market Biosimilars 78

8.2.2 Abraxis Licenses Rights to Biosimilar from Indian Firm Biocon 78

9 M&A Scenario in the Global Vaccines Market 79

9.1 Mergers and Acquisitions 79

9.1.1 Pfizer Acquires Wyeth for $68 billion 82

9.1.2 BioSante Pharmaceuticals Acquires Cell Gensys 82

9.1.3 Johnson & Johnson Acquires 18% Stake in Crucell 82

9.2 Licensing Agreements 83

9.2.1 Discovery Phase 87

9.2.2 Phase I 88

9.2.3 Phase II 89

9.2.4 Phase III 90

9.2.5 Filed for Approval and Approved 91

10 Licensing Agreements of Top 10 Biotech Companies 93

10.1 Amgen Inc 93

10.1.1 Company Overview 93

10.1.2 Licensing Agreements 93

10.2 Genentech (Roche) 94

10.2.1 Company Overview 94

10.2.2 Licensing Agreements 94

10.3 Gilead Sciences 95

10.3.1 Company Overview 95

10.3.2 Licensing Agreements 95

10.4 UCB Pharma 96

10.4.1 Company Overview 96

10.4.2 Licensing Agreements 96

10.5 Genzyme Corporation 96

10.5.1 Company Overview 96

10.5.2 Licensing Agreements 97

10.6 Biogen Idec 98

10.6.1 Company Overview 98

10.6.2 Licensing Agreements 98

10.7 CSL Limited 99

10.7.1 Company Overview 99

10.7.2 Licensing Agreements 99

10.8 Celgene Corporation 99

10.8.1 Company Overview 99

10.8.2 Licensing Agreements 99

10.9 Cephalon 100

10.9.1 Company Overview 100

10.9.2 Licensing Agreements 100

10.10 Actelion Pharmaceuticals Ltd 101

10.10.1 Company Overview 101

10.10.2 Licensing Agreements 101

11 Biotech M&A and Licensing Strategies – Appendix 102

11.1 Marketed Definitions 102

11.2 Abbreviations 102

11.3 Research Methodology 103

11.3.1 Coverage 103

11.3.2 Secondary Research 104

11.3.3 Primary Research 104

11.3.4 Expert Panel Validation 104

11.4 Contact Us 104

11.5 Disclaimer 105

11.6 Sources 105

1.1 List of Tables

Table 1: Biotech M&A and Licensing Strategies, Value of Drugs Going Off-Patent by Therapeutic Area, Global, ($m), 2009–2014 13

Table 2: Biotech M&A and Licensing Strategies, Global, Top M&A Deals, $m, 2009 22

Table 3: Biotech M&A and Licensing Strategies, Global, Top M&A Deals, $m, 2010 24

Table 4: Biotech M&A and Licensing Strategies, Global, Top Licensing Agreements, $m, 2009 34

Table 5: Biotech M&A and Licensing Strategies, Global, Top Licensing Agreements, $m, 2010 34

Table 6: Biotech M&A and Licensing Strategies, Global, Key M&A Activities in RNA Therapies, 2008-2009 35

Table 7: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Discovery/Development Stage Drugs Licensing Agreements, 2008-2009 43

Table 8: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Preclinical Drugs Licensing Agreements, 2008-2009 48

Table 9: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Phase II Drugs Licensing Agreements, 2008-2009 49

Table 10: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Phase III Drugs Licensing Agreements, 2008-2009 50

Table 11: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major M&A Deals Between 2008-2009 51

Table 12: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in the Preclinical Stage, 2008-2009 56

Table 13: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase I, 2008-2009 57

Table 14: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase II, 2008-09 58

Table 15: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase III, 2008-2009 59

Table 16: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Approved Drugs, 2008-09 59

Table 17: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Merger and Acquisitions, 2009 60

Table 18: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Indication (%), 2006–2010 67

Table 19: Biotech M&A and Licensing Strategies, Global Vaccines Market, Top M&A Deals, 2009 81

Table 20: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Discovery Phase, 2009 87

Table 21: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase I, 2009 88

Table 22: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase II, 2009 89

Table 23: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase III, 2009 90

Table 24: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Approval Phase, 2009 91

Table 25: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals for Approved Drugs, 2009 91

Table 26: Biotech M&A and Licensing Strategies, Amgen Inc., Key Licensing Agreements, 2008 and 2009 93

Table 27: Biotech M&A and Licensing Strategies, Genentech, Key Licensing Agreements, 2008 and 2009 94

Table 28: Biotech M&A and Licensing Strategies, Gilead, Key Licensing Agreements, 2008 and 2009 95

Table 29: Biotech M&A and Licensing Strategies, UCB Pharma, Key Licensing Agreements, 2008 and 2009 96

Table 30: Biotech M&A and Licensing Strategies, Genzyme, Key Licensing Agreements, 2008 and 2009 97

Table 31: Biotech M&A and Licensing Strategies, Biogen Idec, Key Licensing Agreements, 2008 and 2009 98

Table 32: Biotech M&A and Licensing Strategies, CSL Limited, Key Licensing Agreements for Drugs, 2008 and 2009 99

Table 33: Biotech M&A and Licensing Strategies, Celgene, Key Licensing Agreements, 2008 and 2009 99

Table 34: Biotech M&A and Licensing Strategies, Cephalon, Key Licensing Agreements, 2008 and 2009 100

Table 35: Biotech M&A and Licensing Strategies, Actelion, Key Licensing Agreements, 2008 and 2009 101

1.2 List of Figures

Figure 1: Biotech M&A and Licensing Strategies, Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009–2014 13

Figure 2: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech, 2009 and 2010 15

Figure 3: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2009 and 2010 16

Figure 4: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2009 17

Figure 5: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2010 18

Figure 6: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2009 19

Figure 7: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2010 20

Figure 8: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2009 and 2010 21

Figure 9: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech, 2009 and 2010 26

Figure 10: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2009 27

Figure 11: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2010 28

Figure 12: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2009 and 2010 29

Figure 13: Biotech M&A and Licensing Strategies, Global, Co-Development Deals in Biotech, 2009 and 2010 30

Figure 14: Biotech M&A and Licensing Strategies, Global, Co-development Deals in Biotech by Geography (%), 2009 31

Figure 15: Biotech M&A and Licensing Strategies, Global, Co-Development Deals in Biotech by Geography (%), 2010 32

Figure 16: Biotech M&A and Licensing Strategies, Global, Co-development Deals in Biotech by Geography (%), 2009 and 2010 33

Figure 17: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Phase (%), 2008-2009 39

Figure 18: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Geography (%), 2008-2009 40

Figure 19: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Deal (%), 2008-2009 41

Figure 20: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Value (%), 2008-2009 42

Figure 21: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements by Phase (%), 2008-09 53

Figure 22: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements By Geography (%), 2008-09 54

Figure 23: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements by Deal Value (%), 2008-2009 55

Figure 24:Biotech M&A and Licensing Strategies, Global Biomarkers Market, Deals by Type (%), 2009 62

Figure 25:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Year of Consolidation, 2009 63

Figure 26:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Geography (%), 2009 64

Figure 27:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Deal Value ($m), 2009 65

Figure 28: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Year, 2006–2010 66

Figure 29: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Indication (%), 2006–2010 67

Figure 30: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Deal Type (%), 2006–2010 68

Figure 31: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Geography (%), 2006–2010 69

Figure 32: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Companies (%), 2006–2010 70

Figure 33: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Value (%), 2005–2010 71

Figure 34: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Geography (%), 2005–2010 72

Figure 35: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Companies (%), 2005–2010 73

Figure 36: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A by Deal Type (%), 2009 79

Figure 37: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A Deals by Geography (%), 2009 80

Figure 38: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A Deals by Value (%), 2009 81

Figure 39: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Phase (%), 2009 83

Figure 40: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances Geography (%), 2009 84

Figure 41: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Deal Value, 2009 85

Figure 42: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Indications (%), 2009 86

Companies mentioned

Amgen Inc

Genentech (Roche)

Gilead Sciences

UCB Pharma

Genzyme Corporation

Biogen Idec

CSL Limited

Celgene Corporation

Cephalon

Actelion Pharmaceuticals Ltd

To order this report:

Biopharmaceutical Industry: Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines

Biopharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Global Biomaterial Market (2010 - 2015)
2. Reportlinker Adds Genetics Reports Bundle
3. Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
4. Reportlinker Adds Biomarkers: Technologies and Global Markets
5. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
6. Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
7. Reportlinker Adds R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment
8. Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips
9. Reportlinker Adds Competitor Analysis: Targeted Therapy of Diabetes
10. Reportlinker Adds China Bio-breeding Industry Report, 2010
11. Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... bioprocess media products engineered to radically streamline culture processes, minimize processing time, ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... Dec. 8, 2016  Partnering to fuel ... Technology Partners of Southeastern Pennsylvania ... parent company of Independence Blue Cross; and Safeguard Scientifics ... intentions for a $6 million funding initiative over a ... Responding to a burgeoning economic vitality in ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
Breaking Biology News(10 mins):